High Purity Amphotericin B: A Safer Antimycotic in AIDS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$110,644.00
Award Year:
2005
Program:
STTR
Phase:
Phase I
Contract:
1R41AI063935-01A1
Award Id:
75870
Agency Tracking Number:
AI063935
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Cumberland Pharmaceuticals, Inc., 2525 West End Ave, Ste 950, Nashville, TN, 37203
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOHNCLEARY
(601) 984-2639
JCLEARY@MEDICINE.UMSMED.EDU
Business Contact:
LEO PAVLIV
(615) 255-0068
AKAZIMI@CUMBERLANDPHARMA.COM
Research Institute:
UNIVERSITY OF MISSISSIPPI

125 OLD CHEMISTRY
P.O. BOX 907
UNIVERSITY, MS, 38677

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Cumberland Pharmaceuticals and the University of Mississippi Mycotic Research Centers' long-term goal will be to improve anti-fungal pharmacotherapy particularly for patients with human immunodeficiency infections (HIV). We are jointly developing a high purity amphotericin B (AmB HP) product for intravenous administration. The nominal purity of AmB HP is 95%; excluding surfactant and buffer that are required for formulation. Although in some cases the increase in purity in comparison to current commercial preparations of AmB is modest, preliminary data from our laboratories indicate that removal of contaminating materials markedly decreases the toxicity to AmB without compromising its antifungal efficacy. Thus, AmB HP promises to be a significant addition to current antifungal therapy by offering a preparation with a higher therapeutic index than is offered by current AmB formulations. In the Phase II of this project we will address the production of AmBHP and filing of an NDA for initiating a clinical trial. The clinical trial results will be used to support an NDA for seeking approval for the use of AmB HP in disseminated mycoses commonly seen in patients with HIV infections or other infections of immunocompromised patients.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government